首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1629606

生技藥品市場、副產品、藥物分類、給藥途徑、購買方式、通路和地區。

Biologics Market, By Product, By Drug Classification, By Route of Administration, By Mode of Purchase, By Distribution Channel,By Geography .

出版日期: 2024年12月17日 | 出版商:

Coherent Market Insights | 英文 210 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球生技藥品市場預計到2024年將達到5.221億美元，預計到2031年將達到10.442億美元，2024年至2031年的年複合成長率為10.4%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	5.221億美元
實際資料	2019-2023	預測期	2024-2031
預測2024-2031年年複合成長率：	10.40%	2031年價值預測	10.442億美元

圖：2024年依地區分類的生技藥品市場佔有率（%）

生技藥品是指由活生物體製成的用於預防、治療或治癒人類疾病的藥物。這包括疫苗、血液成分、過敏原、體細胞、基因療法、組織、重組治療性蛋白質等。全球慢性病的盛行率日益增加，加上老年人口不斷增加，更容易患各種疾病，這可能會推動對生技藥品的需求。生物技術的快速創新和進步使得新型生技藥品的開發成為可能，其安全性、有效性和作用特異性得到提升。這擴大了多種危及生命的疾病的治療選擇，包括癌症、風濕病和自體免疫疾病。監管部門的核准和生技藥品商業化的增加可能會推動市場成長。

市場動態

全球生技藥品市場的成長是由糖尿病、癌症和心血管疾病等慢性病的全球流行以及生技藥品研發醫療保健支出的增加所推動的。對蛋白質藥物的需求不斷成長、先進生技藥品的快速核准以及新型生技藥品候選產品的強大管道也推動市場成長。生物加工和品質分析的持續技術進步使得高產量生產平台的開發成為可能，這些平台有利於在商業規模上經濟高效地製造生技藥品。然而，建立生物製造設施所需的大量資本投資、嚴格的監管標準以及生物分子的複雜性給生物相似藥的開發帶來了挑戰。亞太和拉丁美洲等新興市場為相關人員探索新市場和抵銷市場限制提供了有利的機會。

本研究的主要特點

本報告對全球生技藥品市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。

揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。

提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。

根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球生技藥品市場的主要企業進行了分析。

本研究涵蓋的主要企業包括F. Hoffmann-La Roche Ltd.、AbbVie Inc.、Amgen Inc.、Johnson & Johnson Services, Inc.、Merck & Co.Inc.、Pfizer Inc.、Sanofi S.A.、Gilead Sciences, Inc.、Novartis AG、Bristol-Myers Squibb Company、Regeneron Pharmaceuticals, Inc.、Takeda Pharmaceutical Company Limited、Biogen Inc.、Eli Lilly and Company、Celltrion Healthcare Co., Ltd.等。

本報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

全球生技藥品市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

透過分析全球生技藥品市場時所使用的各種策略矩陣，將有助於相關人員做出決策。

Hoffmann-La Roche Ltd.
AbbVie Inc.
Amgen Inc.
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Pfizer Inc.
Sanofi SA
Gilead Sciences, Inc.
Novartis AG
Bristol-Myers Squibb Company
Regeneron Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Biogen Inc.
Eli Lilly and Company
Celltrion Healthcare Co., Ltd.

第11章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI2663

Global biologics market is estimated to be valued at USD 522.1 Mn in 2024 and is expected to reach USD 1,044.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.4% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 522.1 Mn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	10.40%	2031 Value Projection:	US$ 1,044.2 Mn

Figure. Biologics Market Share (%), By Region 2024

Biologics refers to medicines created from living organisms that are used to prevent, treat, and cure human diseases. These include vaccines, blood components, allergenics, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins. Increasing prevalence of chronic diseases worldwide coupled with rising elderly population prone to various illnesses can boost demand for biologics. Rapid innovations and advancements in biotechnology have enabled development of novel biologic agents with improved safety, efficacy and specificity of action. This has expanded treatment options for several life-threatening conditions such as cancer, rheumatic disorders, and autoimmune diseases. Growing regulatory approvals and commercialization of biologics can drive the market growth.

Market Dynamics

Global biologics market growth is driven by growing prevalence of chronic diseases worldwide such as diabetes, cancer, cardiovascular diseases along with rising healthcare expenditure on biopharmaceutical R&D. Increasing demand for protein-based drugs, rapid approvals of advanced biologics and strong pipeline of novel biologic candidates can also drive the market growth. Constant technological advancements in bioprocessing and quality analytics enables development of high-yield production platforms conducive for cost-effective manufacturing of biologics at commercial scale. However, factors such as high capital investment needs for setting up bio-manufacturing facilities, stringent regulatory norms, and complexity of biological molecules poses challenges in biosimilar development. Emerging markets across developing regions such as Asia Pacific and Latin America offer lucrative opportunities for stakeholders to tap into new geographic territories and offset restraint impact.

Key Features of the Study

This report provides in-depth analysis of the global biologics market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global biologics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Eli Lilly and Company, and Celltrion Healthcare Co., Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biologics market

Market Segmentation

By Product Insights (Revenue, USD Mn, 2019 - 2031)
- Monoclonal Antibodies
- Vaccines
- Recombinant Hormones/Proteins
- Cellular-based Biologics
- Gene-based Biologics
- Others
By Drug Classification Insights (Revenue, USD Mn, 2019 - 2031)
- Branded Drugs
- Generic Drugs
By Route of Administration Insights (Revenue, USD Mn, 2019 - 2031)
- Oral
- Parenteral
- Other Routes
By Mode of Purchase Insights (Revenue, USD Mn, 2019 - 2031)
- Prescription-Based Drugs
- Over-The-Counter Drugs
By Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- F. Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Amgen Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi S.A.
- Gilead Sciences, Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- Eli Lilly and Company
- Celltrion Healthcare Co., Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Biologics Market, By Product
- Global Biologics Market, By Drug Classification
- Global Biologics Market, By Route of Administration
- Global Biologics Market, By Mode of Purchase
- Global Biologics Market, By Distribution Channel
- Global Biologics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Biologics Market, By Product, 2019-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Recombinant Hormones/Proteins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Cellular-based Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Gene-based Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

5. Global Biologics Market, By Drug Classification, 2019-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Branded Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Generic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Biologics Market, By Route of Administration, 2019-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Other Routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Biologics Market, By Mode of Purchase, 2019-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Prescription-Based Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Over-The-Counter Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Biologics Market, By Distribution Channel, 2019-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

9. Global Biologics Market, By Region, 2019 - 2031, (USD Mn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Product, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Drug Classification, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Mode of Purchase, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Product, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Drug Classification, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Mode of Purchase, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Product, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Drug Classification, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Mode of Purchase, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Drug Classification, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Mode of Purchase, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Product, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Drug Classification, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Mode of Purchase, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Product, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Drug Classification, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Mode of Purchase, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc.
Pfizer Inc.
Sanofi S.A.
Gilead Sciences, Inc.
Novartis AG
Bristol-Myers Squibb Company
Regeneron Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Biogen Inc.
Eli Lilly and Company
Celltrion Healthcare Co., Ltd.